Cell Therapeutics About
Cell Therapeutics: About Cell Therapeutics Cell Therapeutics,
Inc. (CTI) is a biopharmaceutical company
with a diversified portfolio of proprietary
oncology drugs. Using genomic information
to develop a personalized approach to
cancer therapy, the company's goal is
to make standard-of-care treatment less
toxic and more effective for individual
patients. CTI is focused on gaining approvals for
its two phase III product candidates,
pixantrone in relapsed aggressive non-Hodgkin's
lymphoma (NHL), and OPAXIO in ovarian
cancer. Pixantrone is a novel compound
designed to improve efficacy and safety
treating cancers normally treated with
anthracyclines. Based on the EXTEND (PIX301)
phase III clinical trial which achieved
its primary efficacy endpoint, CTI submitted
an NDA to the FDA in June 2009 for pixantrone
use in the treatment of relapsed or refractory
aggressive non-Hodgkin's lymphoma (NHL).
Pixantrone has fast track status for the
relapsed / refractory aggressive NHL application.
OPAXIO(tm) (paclitaxel poliglumex) is
a biologically enhanced chemotherapeutic
that links paclitaxel to a biodegradable
polyglutamate polymer. It is in pivotal
trials for ovarian and non-small cell
lung (NSCLC) cancers. Another product is in phase II clinical
development. Brostallicin is a unique
minor groove binding agent being studied
in advanced or metastatic soft tissue
sarcoma and myxoid liposarcoma. For more information: CellTherapeutics.com
More on
Cell Therapeutics :
Key
Statistics for Cell Therapeutics
Basic Chart
for Cell Therapeutics